"GeoArea_Code","GeoArea_Desc","ISO3CD","X","Y","GoalCode","GoalDesc","TargetCode","TargetDesc","IndicatorCode","IndicatorDesc","IndicatorTier","SeriesCode","SeriesDesc","SeriesRelease","Units_Code","Units_Desc","ReportingType_Code","ReportingType_Desc","Value_2008","Value_2009","Value_2010","Value_2011","Value_2012","Value_2013","Value_2014","Value_2015","Value_2016","Latest_Year","Latest_Value","Nature_Desc","Source"
"4","Afghanistan","AFG","66.02688198","33.83160199","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","40","65","65",2016.0,"65","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"8","Albania","ALB","20.06660928","41.13897007","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","99","99","99","99","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"10","Antarctica","ATA","21.47585697","-80.40897662","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"12","Algeria","DZA","2.678164227","28.15940032","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","61",2016.0,"61","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"16","American Samoa","ASM","-170.7187269","-14.30587306","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"20","Andorra","AND","1.576257417","42.54548611","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","93","92","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"24","Angola","AGO","17.57817062","-12.33724746","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","9","45","58","58",2016.0,"58","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"28","Antigua and Barbuda","ATG","-61.7999755","17.07761471","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"31","Azerbaijan","AZE","50.01064725","40.39229544","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","64","94","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"32","Argentina","ARG","-65.14563274","-35.19446255","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","41","86","89","82","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"36","Australia","AUS","134.3499412","-25.57717202","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","91","91","91","91","91","91","91","93","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"40","Austria","AUT","14.14172472","47.58704857","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"44","Bahamas","BHS","-78.05111663","24.69546597","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","3","1","1","37","97","96","95","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"48","Bahrain","BHR","50.5490754","26.04407747","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","14","96","99","99","99","99","98","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"50","Bangladesh","BGD","89.17660788","22.86961622","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","48","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"51","Armenia","ARM","44.93839317","40.29499741","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","44","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"52","Barbados","BRB","-59.5346489","13.13648273","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","75","78","81","84","87","90","97","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"56","Belgium","BEL","4.660976456","50.64104975","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","93","93","93","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"60","Bermuda","BMU","-64.78155012","32.27881922","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"64","Bhutan","BTN","90.45098484","27.39598568","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"68","Bolivia (Plurinational State of)","BOL","-64.66224284","-16.71273412","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","56","96","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"70","Bosnia and Herzegovina","BIH","17.78584332","44.16845548","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"72","Botswana","BWA","23.81380223","-22.18810073","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","52","72","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"74","Bouvet Island","BVT","3.410732868","-54.43295905","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"76","Brazil","BRA","-53.08432878","-10.77668561","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","24","82","88","94","93","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"84","Belize","BLZ","-88.70199554","17.19965901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"86","British Indian Ocean Territory","IOT","72.38715553","-7.299281071","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"90","Solomon Islands","SLB","160.1584117","-9.622391719","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","42","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"92","British Virgin Islands","VGB","-64.63294223","18.42256578","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"96","Brunei Darussalam","BRN","114.6288563","4.49736984","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"100","Bulgaria","BGR","25.23763153","42.75731323","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","69","94","94","94","92","90","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"104","Myanmar","MMR","96.51752295","21.19332882","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","14",2016.0,"14","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"108","Burundi","BDI","29.89080992","-3.366387428","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","14","96","96","95","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"112","Belarus","BLR","28.04940161","53.54193075","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"116","Cambodia","KHM","104.922836","12.71163737","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","68","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"120","Cameroon","CMR","12.7419827","5.692387031","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","23","84","88","87","85","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"124","Canada","CAN","-101.6575058","57.72360191","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","42","50","58","66","73","79","79","79","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"132","Cabo Verde","CPV","-23.63544151","15.07791834","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"136","Cayman Islands","CYM","-81.16740559","19.32266656","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"140","Central African Republic","CAF","20.93559492","7.003720791","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","8","47","23","47","47","47",2016.0,"47","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"144","Sri Lanka","LKA","80.70489654","7.614693343","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"148","Chad","TCD","18.66618401","15.36279341","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"152","Chile","CHL","-71.23029019","-35.2652885","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","54","82","79","92","90","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"156","China","CHN","104.1403375","32.30955217","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"162","Christmas Island","CXR","105.6426067","-10.4882473","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"166","Cocos (Keeling) Islands","CCK","96.82633757","-12.18600682","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"170","Colombia","COL","-73.07446751","3.888209046","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","22","46","84","87","89","91","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"174","Comoros","COM","43.34234565","-11.66121732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"175","Mayotte","MYT","45.14015057","-12.82217691","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"178","Congo","COG","15.22052612","-0.840544119","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","10","85","85","80","80",2016.0,"80","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"180","Democratic Republic of the Congo","COD","23.65496507","-2.877154732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","9","13","31","61","73","77",2016.0,"77","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"184","Cook Islands","COK","-159.7711391","-21.22696458","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"188","Costa Rica","CRI","-84.19712782","9.970998683","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","48","94","68","89","94","83","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"191","Croatia","HRV","17.95874553","45.45172212","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"192","Cuba","CUB","-79.54460144","22.10030366","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"196","Cyprus","CYP","33.22285964","35.05659437","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","81","81",2016.0,"81","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"203","Czechia","CZE","15.33151382","49.73913871","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"204","Benin","BEN","2.339933594","9.65401646","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","36","67","70","71","75","75",2016.0,"75","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"208","Denmark","DNK","9.326571283","56.03829721","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","86","88","90","93","90","93","91","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"212","Dominica","DMA","-61.3493756","15.43391378","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"214","Dominican Republic","DOM","-70.49847576","18.89832088","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","27","22","30",2016.0,"30","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"218","Ecuador","ECU","-78.37005241","-1.447785891","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","17","71","94","90","86","81","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"222","El Salvador","SLV","-88.86862995","13.73603564","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","69","98","94","92","86","98","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"226","Equatorial Guinea","GNQ","10.46535826","1.565792376","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"231","Ethiopia","ETH","39.63505296","8.631223181","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","12","38","63","76","76","76",2016.0,"76","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"232","Eritrea","ERI","38.11074289","16.12894644","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"233","Estonia","EST","25.84093481","58.68487172","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"234","Faroe Islands","FRO","-7.122044325","62.21228119","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"238","Falkland Islands (Malvinas)","FLK","-58.75246778","-51.74562601","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"239","South Georgia and the South Sandwich Islands","SGS","-36.90662765","-54.20736749","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"242","Fiji","FJI","177.9660884","-17.83301566","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","87","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"246","Finland","FIN","23.308447","61.91586738","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","92","92","92","92","92","92","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"248","land Islands","ALA","19.80945969","60.1544901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"250","France","FRA","2.457288129","46.62660861","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","89","89","89","89","89","90","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"254","French Guiana","GUF","-53.23619089","3.922673437","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"258","French Polynesia","PYF","-149.4052367","-17.67709294","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"260","French Southern Territories","ATF","69.64849091","-49.6068576","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"262","Djibouti","DJI","42.18274707","11.56004161","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","82","78","82","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"266","Gabon","GAB","11.78727747","-0.60687619","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"268","Georgia","GEO","43.3713615","42.04813028","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","16","75",2016.0,"75","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"270","Gambia","GMB","-15.39944785","13.45295927","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","99","95","98","96","96","97","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"275","State of Palestine","PSE","35.25694122","31.94347933","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","25","97","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"276","Germany","DEU","10.3806066","51.08862743","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","68","85","86","86","86","86","86","86","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"288","Ghana","GHA","-1.205623522","7.964825185","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","43","89","99","88","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"292","Gibraltar","GIB","-5.347561686","36.13895036","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"296","Kiribati","KIR","-157.5643005","1.768837732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","40","57","74","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"300","Greece","GRC","22.58307827","39.47301873","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","32","32","96","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"304","Greenland","GRL","-41.39371316","74.75625681","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"308","Grenada","GRD","-61.68248568","12.11238395","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"312","Guadeloupe","GLP","-61.64762115","16.14416917","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"316","Guam","GUM","144.7029305","13.35485404","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"320","Guatemala","GTM","-91.2312746","15.00273719","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","24","51","82","81",2016.0,"81","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"324","Guinea","GIN","-11.28173419","11.00210343","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"328","Guyana","GUY","-58.97322037","4.788012784","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","50","90","96","97","94","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"332","Haiti","HTI","-72.33640958","18.40426539","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"334","Heard Island and McDonald Islands","HMD","73.52633626","-53.09106147","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"336","Holy See","VAT","12.45315803","41.90343751","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"340","Honduras","HND","-86.59974381","14.82243161","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","97","97","97","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"344","China, Hong Kong Special Administrative Region","HKG","114.0266445","22.41749934","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"348","Hungary","HUN","19.41221519","47.1651448","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","84","90","92","93","91","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"352","Iceland","ISL","-19.02116966","64.79134763","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","86","88","90","91","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"356","India","IND","79.3608464","22.34642074","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"360","Indonesia","IDN","113.9174","-0.994582204","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"364","Iran (Islamic Republic of)","IRN","54.19766348","32.74370885","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"368","Iraq","IRQ","43.76606267","33.05013795","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"372","Ireland","IRL","-7.121425272","53.25274054","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","43","90","91","91","92","92","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"376","Israel","ISR","34.62277992","31.06164552","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","92","93","94","94","94","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"380","Italy","ITA","12.57022427","42.79917282","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","60","66","71","76","82","87","87","89","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"384","Cte d'Ivoire","CIV","-5.552690016","7.62211586","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","2","72","83",2016.0,"83","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"388","Jamaica","JAM","-77.31068409","18.15616857","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"392","Japan","JPN","139.2716103","36.6554539","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","96","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"398","Kazakhstan","KAZ","66.65359159","48.01963494","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","37","52","58","74","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"400","Jordan","JOR","37.13024774","30.65365973","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"404","Kenya","KEN","37.86096816","0.534797278","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","85","82","75","81","75","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"408","Democratic People's Republic of Korea","PRK","127.1803633","40.1462645","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"410","Republic of Korea","KOR","127.8610254","36.45201023","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","97","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"414","Kuwait","KWT","47.49305029","29.53949468","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","98","99","99","99","94","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"417","Kyrgyzstan","KGZ","74.52324839","41.46204516","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"418","Lao People's Democratic Republic","LAO","101.9901968","20.27482773","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","72","77","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"422","Lebanon","LBN","35.89391711","33.92152458","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"426","Lesotho","LSO","28.25362195","-29.58041814","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","29","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"428","Latvia","LVA","26.42461876","56.64196636","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","76","55","83","83","82","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"430","Liberia","LBR","-9.311879038","6.448381009","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","45","56","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"434","Libya","LBY","18.0295985","27.04042819","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","39","71","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"438","Liechtenstein","LIE","9.552985019","47.14167005","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"440","Lithuania","LTU","23.90517807","55.33680309","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"442","Luxembourg","LUX","6.092656563","49.77679538","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","86","86","86","95","95","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"446","China, Macao Special Administrative Region","MAC","113.5665388","22.1237259","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"450","Madagascar","MDG","46.6982339","-19.38514785","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","76","72","69","76",2016.0,"76","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"454","Malawi","MWI","33.4884625","-13.40819859","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","99","89","87","88","83",2016.0,"83","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"458","Malaysia","MYS","116.8346314","5.452415309","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"462","Maldives","MDV","73.09672546","-0.614385021","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"466","Mali","MLI","-3.522016039","17.35311254","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","56","68","71","73","53","70",2016.0,"70","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"470","Malta","MLT","14.44617519","35.89194275","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"474","Martinique","MTQ","-60.91544135","14.56086108","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"478","Mauritania","MRT","-10.33187259","20.26089546","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","1","71","71","73",2016.0,"73","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"480","Mauritius","MUS","57.568022","-20.28581998","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","10",2016.0,"10","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"484","Mexico","MEX","-102.5148166","23.93378032","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","14","46","92","98","99","84","94","93","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"492","Monaco","MCO","7.424214814","43.73532918","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"496","Mongolia","MNG","103.0728057","46.83892054","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"498","Republic of Moldova","MDA","28.4650624","47.20236795","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","1","28","71","77",2016.0,"77","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"499","Montenegro","MNE","19.25214024","42.78717043","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"500","Montserrat","MSR","-62.19261223","16.73558313","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"504","Morocco","MAR","-6.281942841","31.8440131","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","1","23","72","80","90","95","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"508","Mozambique","MOZ","38.18479941","-14.27963886","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","45","73","80","80",2016.0,"80","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"512","Oman","OMN","57.87743482","21.98805614","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","96","99","99","99","99","98","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"516","Namibia","NAM","17.21907885","-22.13817068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","81","81",2016.0,"81","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"520","Nauru","NRU","166.92313","-0.528742623","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"524","Nepal","NPL","83.94678863","28.25866332","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","5","46",2016.0,"46","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"528","Netherlands","NLD","5.331480568","51.86728884","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","96","96","96","96","96","95","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"530","Netherlands Antilles","ANT","-68.30676179","12.22720635","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"531","Curaao","CUW","-68.95033464","12.15058042","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"533","Aruba","ABW","-69.97050586","12.50878756","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"534","Sint Maarten (Dutch part)","SXM","-63.06198692","18.03926508","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"540","New Caledonia","NCL","165.5067368","-21.41742531","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"548","Vanuatu","VUT","167.0679779","-15.34445547","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"554","New Zealand","NZL","170.4755673","-43.98721568","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","87","89","92","92","93","93","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"558","Nicaragua","NIC","-85.03060315","12.84210839","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","61","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"562","Niger","NER","9.400167877","17.42143036","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","13","49","64",2016.0,"64","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"566","Nigeria","NGA","8.097363256","9.585789025","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","13","26",2016.0,"26","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"570","Niue","NIU","-169.8601693","-19.05000475","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"574","Norfolk Island","NFK","167.9515548","-29.03230018","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"578","Norway","NOR","11.47846389","61.34311134","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","91","91","92","93","93","91","93","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"580","Northern Mariana Islands","MNP","145.7582114","15.19099517","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"581","US Minor Outlying Islands","UMI","-162.4343752","5.874443968","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"583","Micronesia (Federated States of)","FSM","158.225216","6.880670092","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","70","63","60","61","64","67","63",2016.0,"63","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"583","Micronesia, Federated States of","FSM","158.225216","6.880670092","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"584","Marshall Islands","MHL","171.0839119","7.110213497","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","49","24","35","46","38","29","75","51",2016.0,"51","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"585","Palau","PLW","134.5733878","7.502307591","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","7","18","45","61","82","93","93","95","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"586","Pakistan","PAK","68.80479684","29.36491634","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","66","72","72","72",2016.0,"72","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"591","Panama","PAN","-81.26616623","8.450965746","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","48","55","62","68","75","82","83",2016.0,"83","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"598","Papua New Guinea","PNG","145.8587761","-6.756057077","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","20","20",2016.0,"20","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"600","Paraguay","PRY","-60.54854225","-21.70216237","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","82","90","88","92","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"604","Peru","PER","-71.82093277","-13.58939705","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","9","83","82","89","85","86","90","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"608","Philippines","PHL","120.8601418","14.16591706","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","35","17","36",2016.0,"36","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"612","Pitcairn","PCN","-128.3225873","-24.37538456","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"616","Poland","POL","19.40660158","52.1226733","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"620","Portugal","PRT","-7.961599811","39.68509315","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"624","Guinea-Bissau","GNB","-14.40182514","12.11760394","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","10","80",2016.0,"80","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"626","Timor-Leste","TLS","125.9451052","-8.797497247","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"630","Puerto Rico","PRI","-66.47591017","18.22753799","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"634","Qatar","QAT","51.19152467","25.28355379","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","99","97","98","92","99","94","95","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"638","Runion","REU","55.53171398","-21.13183266","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"642","Romania","ROU","24.98481009","45.83893563","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"643","Russian Federation","RUS","99.01404926","61.61899849","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","35",2016.0,"35","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"646","Rwanda","RWA","29.92310194","-1.999842114","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","97","97","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"652","Saint Barthlemy","BLM","-62.83173536","17.89513362","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"654","Saint Helena","SHN","-5.705752501","-15.96503946","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"659","Saint Kitts and Nevis","KNA","-62.76628613","17.33994219","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"660","Anguilla","AIA","-63.05651612","18.21525315","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"662","Saint Lucia","LCA","-60.96529553","13.89405601","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"663","Saint Martin (French Part)","MAF","-63.04505461","18.0882685","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"666","Saint Pierre and Miquelon","SPM","-56.33682442","46.85812735","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"670","Saint Vincent and the Grenadines","VCT","-61.19024321","13.24627968","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"674","San Marino","SMR","12.46329038","43.93841766","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","12",2016.0,"12","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"678","Sao Tome and Principe","STP","6.609772265","0.241554875","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","97","95","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"682","Saudi Arabia","SAU","44.54763347","24.12594211","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","98","98","98","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"686","Senegal","SEN","-14.46636926","14.35920905","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","81","89","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"688","Serbia","SRB","20.805876","44.03145697","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"690","Seychelles","SYC","55.46561591","-4.678053059","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"694","Sierra Leone","SLE","-11.78306584","8.568604164","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","75","92","92","83","86","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"702","Singapore","SGP","103.8107883","1.361009155","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","17","22","40","52","60","69","75","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"703","Slovakia","SVK","19.48495604","48.70741446","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","99","99","99","99","98","96","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"704","Viet Nam","VNM","105.802499","10.09643079","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"705","Slovenia","SVN","14.82209486","46.11958061","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","49","50",2016.0,"50","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"706","Somalia","SOM","46.20367477","4.406485729","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"710","South Africa","ZAF","24.67184355","-29.99957544","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","10","58","62","70","69","72","77","69",2016.0,"69","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"716","Zimbabwe","ZWE","29.86909584","-19.00075492","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","21","95","91","87","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"724","Spain","ESP","-3.554078296","40.39211472","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"728","South Sudan","SSD","30.32618773","7.290839152","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"732","Western Sahara","ESH","-13.13515523","24.66265342","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"736","Sudan","SDN","29.95650159","16.02643066","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"740","Suriname","SUR","-55.90626394","4.132603197","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"744","Svalbard and Jan Mayen Islands","SJM","13.38071013","78.82894131","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"748","Eswatini","SWZ","31.50149288","-26.56471011","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","67","90","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"752","Sweden","SWE","14.3775338","60.60103109","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","60","98","98","98","97","97","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"756","Switzerland","CHE","8.223158","46.96617097","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","13","25","37","50","62","75","80","81","81",2016.0,"81","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"760","Syrian Arab Republic","SYR","38.50466565","35.01676176","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"762","Tajikistan","TJK","69.294998","38.43069666","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"764","Thailand","THA","101.0202951","15.13089239","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"768","Togo","TGO","0.97835765","8.532096072","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","34","86","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"772","Tokelau","TKL","-171.8154473","-9.214545558","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"776","Tonga","TON","-175.1959991","-21.19511329","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"780","Trinidad and Tobago","TTO","-61.29389504","10.41877263","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","39","80","95","93","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"784","United Arab Emirates","ARE","53.98279159","23.43322219","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","94","95","96","98","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"788","Tunisia","TUN","9.572737411","34.11439971","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"792","Turkey","TUR","35.42890329","38.9899684","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","97","93","96","97","97","96","97","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"795","Turkmenistan","TKM","58.9787665","40.0912346","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"796","Turks and Caicos Islands","TCA","-71.745121","21.80780585","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"798","Tuvalu","TUV","178.6679611","-7.460048071","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"800","Uganda","UGA","32.39100438","1.279557331","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","50","66","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"804","Ukraine","UKR","31.40270802","49.00735945","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"807","Macedonia, Republic of","MKD","21.7007909","41.60048068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"818","Egypt","EGY","29.77468534","26.57438204","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"826","United Kingdom","GBR","-2.23830539","53.27691757","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"826","United Kingdom of Great Britain and Northern Ireland","GBR","-2.23830539","53.27691757","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","89","90","92","93","93","93","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"831","Guernsey","GGY","-2.200712402","49.71561166","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"832","Jersey","JEY","-2.136773508","49.22353354","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"833","Isle of Man","IMN","-4.538190305","54.22880901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"834","Tanzania, United Republic of","TZA","34.80521182","-6.265332606","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"834","United Republic of Tanzania","TZA","34.80521182","-6.265332606","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","80","93","95","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"840","United States of America","USA","-99.13830311","39.5277871","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","93","93","94","92","92","93","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"850","United States Virgin Islands","VIR","-64.76960113","17.73297693","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"854","Burkina Faso","BFA","-1.742843829","12.27491081","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","91","91","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"858","Uruguay","URY","-56.01387025","-32.8002838","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","91","92","93","93","95","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"860","Uzbekistan","UZB","63.11944558","41.77560518","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"862","Venezuela (Bolivarian Republic of)","VEN","-66.15642084","7.121324748","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","24","7",2016.0,"7","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"876","Wallis and Futuna Islands","WLF","-176.2034788","-13.28471201","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"882","Samoa","WSM","-172.4430749","-13.61541469","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"887","Yemen","YEM","45.22389143","15.22242099","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","41","67","73","73","69","71",2016.0,"71","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"894","Zambia","ZMB","27.850329","-14.59701056","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","77","81","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
